INTRODUCTION: To assess the efficacy of an abbreviated Stanford V regimen in patients with early-stage Hodgkin lymphoma (HL). PATIENTS AND METHODS PATIENTS: with untreated nonbulky stage I-IIA supradiaphragmatic HL were eligible for the G4 study. Stanford V chemotherapy was administered for 8 weeks followed by radiation therapy (RT) 30 Gy to involved fields (IF). Freedom from progression (FFP), disease-specific survival (DSS) and overall survival (OS) were estimated. RESULTS: All 87 enrolled patients completed the abbreviated regimen. At a median follow-up of 10 years, FFP, DSS and OS are 94%, 99% and 94%, respectively. Therapy was well tolerated with no treatment-related deaths. CONCLUSIONS: Mature results of the abbreviated Stanford V regimen in nonbulky early-stage HL are excellent and comparable to the results from other contemporary therapies.
INTRODUCTION: To assess the efficacy of an abbreviated Stanford V regimen in patients with early-stage Hodgkin lymphoma (HL). PATIENTS AND METHODS PATIENTS: with untreated nonbulky stage I-IIA supradiaphragmatic HL were eligible for the G4 study. Stanford V chemotherapy was administered for 8 weeks followed by radiation therapy (RT) 30 Gy to involved fields (IF). Freedom from progression (FFP), disease-specific survival (DSS) and overall survival (OS) were estimated. RESULTS: All 87 enrolled patients completed the abbreviated regimen. At a median follow-up of 10 years, FFP, DSS and OS are 94%, 99% and 94%, respectively. Therapy was well tolerated with no treatment-related deaths. CONCLUSIONS: Mature results of the abbreviated Stanford V regimen in nonbulky early-stage HL are excellent and comparable to the results from other contemporary therapies.
Authors: Ralph M Meyer; Mary K Gospodarowicz; Joseph M Connors; Robert G Pearcey; Woodrow A Wells; Jane N Winter; Sandra J Horning; A Rashid Dar; Chaim Shustik; Douglas A Stewart; Michael Crump; Marina S Djurfeldt; Bingshu E Chen; Lois E Shepherd Journal: N Engl J Med Date: 2011-12-11 Impact factor: 91.245
Authors: Andreas Engert; Annette Plütschow; Hans Theodor Eich; Andreas Lohri; Bernd Dörken; Peter Borchmann; Bernhard Berger; Richard Greil; Kay C Willborn; Martin Wilhelm; Jürgen Debus; Michael J Eble; Martin Sökler; Antony Ho; Andreas Rank; Arnold Ganser; Lorenz Trümper; Carsten Bokemeyer; Hartmut Kirchner; Jörg Schubert; Zdenek Král; Michael Fuchs; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Volker Diehl Journal: N Engl J Med Date: 2010-08-12 Impact factor: 91.245
Authors: Bastian von Tresckow; Annette Plütschow; Michael Fuchs; Beate Klimm; Jana Markova; Andreas Lohri; Zdenek Kral; Richard Greil; Max S Topp; Julia Meissner; Josée M Zijlstra; Martin Soekler; Harald Stein; Hans T Eich; Rolf P Mueller; Volker Diehl; Peter Borchmann; Andreas Engert Journal: J Clin Oncol Date: 2012-01-23 Impact factor: 44.544
Authors: Marie L De Bruin; Judith Sparidans; Mars B van't Veer; Evert M Noordijk; Marieke W J Louwman; Josée M Zijlstra; Hendrik van den Berg; Nicola S Russell; Annegien Broeks; Margreet H A Baaijens; Berthe M P Aleman; Flora E van Leeuwen Journal: J Clin Oncol Date: 2009-08-10 Impact factor: 44.544
Authors: Hans Theodor Eich; Volker Diehl; Helen Görgen; Thomas Pabst; Jana Markova; Jürgen Debus; Anthony Ho; Bernd Dörken; Andreas Rank; Anca-Ligia Grosu; Thomas Wiegel; Johann Hinrich Karstens; Richard Greil; Normann Willich; Heinz Schmidberger; Hartmut Döhner; Peter Borchmann; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Andreas Engert Journal: J Clin Oncol Date: 2010-08-16 Impact factor: 44.544
Authors: Christophe Fermé; Houchingue Eghbali; Jacobus H Meerwaldt; Chantal Rieux; Jacques Bosq; Françoise Berger; Théodore Girinsky; Pauline Brice; Mars B van't Veer; Jan A Walewski; Pierre Lederlin; Umberto Tirelli; Patrice Carde; Eric Van den Neste; Emmanuel Gyan; Mathieu Monconduit; Marine Diviné; John M M Raemaekers; Gilles Salles; Evert M Noordijk; Geert-Jan Creemers; Jean Gabarre; Anton Hagenbeek; Oumédaly Reman; Michel Blanc; José Thomas; Brigitte Vié; Johanna C Kluin-Nelemans; Fernando Viseu; Joke W Baars; Philip Poortmans; Pieternella J Lugtenburg; Christian Carrie; Jérôme Jaubert; Michel Henry-Amar Journal: N Engl J Med Date: 2007-11-08 Impact factor: 91.245
Authors: Sughosh Dhakal; Ranjana Advani; Leslie K Ballas; Bouthaina S Dabaja; Christopher R Flowers; Chul S Ha; Bradford S Hoppe; Nancy P Mendenhall; Monika L Metzger; John P Plastaras; Kenneth B Roberts; Ronald Shapiro; Sonali M Smith; Stephanie A Terezakis; Karen M Winkfield; Anas Younes; Louis S Constine Journal: Am J Clin Oncol Date: 2016-12 Impact factor: 2.339
Authors: Richard T Hoppe; Ranjana H Advani; Weiyun Z Ai; Richard F Ambinder; Patricia Aoun; Celeste M Bello; Cecil M Benitez; Philip J Bierman; Kristie A Blum; Robert Chen; Bouthaina Dabaja; Andres Forero; Leo I Gordon; Francisco J Hernandez-Ilizaliturri; Ephraim P Hochberg; Jiayi Huang; Patrick B Johnston; Nadia Khan; David G Maloney; Peter M Mauch; Monika Metzger; Joseph O Moore; David Morgan; Craig H Moskowitz; Carolyn Mulroney; Matthew Poppe; Rachel Rabinovitch; Stuart Seropian; Christina Tsien; Jane N Winter; Joachim Yahalom; Jennifer L Burns; Hema Sundar Journal: J Natl Compr Canc Netw Date: 2015-05 Impact factor: 11.908
Authors: Ranjana H Advani; Richard T Hoppe; Lauren S Maeda; David M Baer; Joseph Mason; Saul A Rosenberg; Sandra J Horning Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-08 Impact factor: 7.038
Authors: Margaretha G M Roemer; Ranjana H Advani; Azra H Ligon; Yasodha Natkunam; Robert A Redd; Heather Homer; Courtney F Connelly; Heather H Sun; Sarah E Daadi; Gordon J Freeman; Philippe Armand; Bjoern Chapuy; Daphne de Jong; Richard T Hoppe; Donna S Neuberg; Scott J Rodig; Margaret A Shipp Journal: J Clin Oncol Date: 2016-04-11 Impact factor: 44.544
Authors: Ryan C Lynch; Vandana Sundaram; Manisha Desai; Solomon Henry; Douglas Wood; Sarah Daadi; Richard T Hoppe; Ranjana Advani Journal: JCO Oncol Pract Date: 2020-05-05